PIK3CA and neoplasm: In tumors with both EGFR and PIK3CA mutations, treatment with gefitinib showed no effect compared to placebo with tumor volume increasing roughly by 7.5mm\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$^3$$\end{document}3/day over the first 20 days (Fig. 6C and D).